Example: biology
E 2 E Pharmacovigilance Planning (Pvp)
LIMITATIONS OF THE HUMAN SAFETY DATABASE Limitations of the safety database (e.g., related to the size of the study population, study inclusion/exclusion criteria) should be considered, and the implications of such limitations with respect to predicting the safety of the product in the marketplace should be explicitly discussed.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Guide to Application for Registration of Medicinal Products
moh.gov.bn3.31 All applications for medicinal product registration are to be made by submission of the required documents which are in line with the ASEAN Common Technical Dossier (ACTD) for the registration of pharmaceuticals for human use and …
QUALITY RISK MANAGEMENT - ICH
database.ich.orgREQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE QUALITY RISK MANAGEMENT Q9 Current Step 4 version dated 9 November 2005 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in …
South African good clinical practice guidelines. 2nd edition
www.kznhealth.gov.zaPolicy; the University of Johannesburg, Pfizer Global Pharmaceuticals; GlaskoSmithKline Beecham (Southern African Region) and all other contributors. DIRECTOR-GENERAL: HEALTH Guidelines for Good Practice in the Conduct of Clinical Trials with Human Participants in South Africa 3
TECHNICAL AND REGULATORY CONSIDERATIONS FOR …
database.ich.orgTECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE . ICH HARMONISED GUIDELINE . TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT . Q12 . Final version . Adopted on 20 November 2019 . This Guideline has been developed by the appropriate ICH Expert …
VOLUME 2A Procedures for marketing authorisation CHAPTER …
ec.europa.eu• special, simplified registration of traditional herbal medicinal products which are not falling within the scope of Article 16d(1), cf. Article 16g(1) of Directive 2001/83/EC • products falling within the transitional arrangements for Cyprus, Lithuania, Malta, Poland and Slovenia upon their accession to the EU, cf. the Act of Accession4.
E3 Step 5 Questions and Answers - European Medicines …
www.ema.europa.euE3- questionsand answers (R1) EMA/CHMP/ICH/435606/2012 Page 2/10 E3 - questions and answers (R1) 1. Content and structure Date of Approval Question Answer